221 related articles for article (PubMed ID: 10945639)
1. The oncogenic properties of the HMG-I gene family.
Wood LJ; Maher JF; Bunton TE; Resar LM
Cancer Res; 2000 Aug; 60(15):4256-61. PubMed ID: 10945639
[TBL] [Abstract][Full Text] [Related]
2. Tumor promoter induces high mobility group HMG-Y protein expression in transformation-sensitive but not -resistant cells.
Cmarik JL; Li Y; Ogram SA; Min H; Reeves R; Colburn NH
Oncogene; 1998 Jul; 16(26):3387-96. PubMed ID: 9692546
[TBL] [Abstract][Full Text] [Related]
3. HMG-I/Y, a new c-Myc target gene and potential oncogene.
Wood LJ; Mukherjee M; Dolde CE; Xu Y; Maher JF; Bunton TE; Williams JB; Resar LM
Mol Cell Biol; 2000 Aug; 20(15):5490-502. PubMed ID: 10891489
[TBL] [Abstract][Full Text] [Related]
4. Elevated high mobility group-I(Y) gene expression is associated with progressive transformation of mouse mammary epithelial cells.
Ram TG; Reeves R; Hosick HL
Cancer Res; 1993 Jun; 53(11):2655-60. PubMed ID: 8495429
[TBL] [Abstract][Full Text] [Related]
5. HMG-I/Y is a c-Jun/activator protein-1 target gene and is necessary for c-Jun-induced anchorage-independent growth in Rat1a cells.
Hommura F; Katabami M; Leaner VD; Donninger H; Sumter TF; Resar LM; Birrer MJ
Mol Cancer Res; 2004 May; 2(5):305-14. PubMed ID: 15192124
[TBL] [Abstract][Full Text] [Related]
6. Decreased tumorigenicity of c-Myc-transformed fibroblasts expressing active USF2.
Choe C; Chen N; Sawadogo M
Exp Cell Res; 2005 Jan; 302(1):1-10. PubMed ID: 15541720
[TBL] [Abstract][Full Text] [Related]
7. HMGI(Y) and HMGI-C dysregulation: a common occurrence in human tumors.
Tallini G; Dal Cin P
Adv Anat Pathol; 1999 Sep; 6(5):237-46. PubMed ID: 10472377
[TBL] [Abstract][Full Text] [Related]
8. Association of c-myc overexpression and hyperproliferation with arsenite-induced malignant transformation.
Chen H; Liu J; Zhao CQ; Diwan BA; Merrick BA; Waalkes MP
Toxicol Appl Pharmacol; 2001 Sep; 175(3):260-8. PubMed ID: 11559025
[TBL] [Abstract][Full Text] [Related]
9. Induction of high mobility group I architectural transcription factors in proliferating vascular smooth muscle in vivo and in vitro.
Chin MT; Pellacani A; Hsieh CM; Lin SS; Jain MK; Patel A; Huggins GS; Reeves R; Perrella MA; Lee ME
J Mol Cell Cardiol; 1999 Dec; 31(12):2199-205. PubMed ID: 10640447
[TBL] [Abstract][Full Text] [Related]
10. HMG-I(Y) recognizes base-unpairing regions of matrix attachment sequences and its increased expression is directly linked to metastatic breast cancer phenotype.
Liu WM; Guerra-Vladusic FK; Kurakata S; Lupu R; Kohwi-Shigematsu T
Cancer Res; 1999 Nov; 59(22):5695-703. PubMed ID: 10582687
[TBL] [Abstract][Full Text] [Related]
11. The oncogenic potential of the high mobility group box protein Sox3.
Xia Y; Papalopulu N; Vogt PK; Li J
Cancer Res; 2000 Nov; 60(22):6303-6. PubMed ID: 11103788
[TBL] [Abstract][Full Text] [Related]
12. Expression of the HMGI(Y) gene products in human neuroblastic tumours correlates with differentiation status.
Giannini G; Kim CJ; Di Marcotullio L; Manfioletti G; Cardinali B; Cerignoli F; Ristori E; Zani M; Frati L; Screpanti I; Guilino A
Br J Cancer; 2000 Dec; 83(11):1503-9. PubMed ID: 11076660
[TBL] [Abstract][Full Text] [Related]
13. The four-and-a-half-LIM protein 2 (FHL2) is overexpressed in gliomas and associated with oncogenic activities.
Li M; Wang J; Ng SS; Chan CY; Chen AC; Xia HP; Yew DT; Wong BC; Chen Z; Kung HF; Lin MC
Glia; 2008 Sep; 56(12):1328-38. PubMed ID: 18615633
[TBL] [Abstract][Full Text] [Related]
14. A modest reduction in c-myc expression has minimal effects on cell growth and apoptosis but dramatically reduces susceptibility to Ras and Raf transformation.
Bazarov AV; Adachi S; Li SF; Mateyak MK; Wei S; Sedivy JM
Cancer Res; 2001 Feb; 61(3):1178-86. PubMed ID: 11221849
[TBL] [Abstract][Full Text] [Related]
15. The high-mobility group A1 gene up-regulates cyclooxygenase 2 expression in uterine tumorigenesis.
Tesfaye A; Di Cello F; Hillion J; Ronnett BM; Elbahloul O; Ashfaq R; Dhara S; Prochownik E; Tworkoski K; Reeves R; Roden R; Ellenson LH; Huso DL; Resar LM
Cancer Res; 2007 May; 67(9):3998-4004. PubMed ID: 17483309
[TBL] [Abstract][Full Text] [Related]
16. Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1.
Eischen CM; Packham G; Nip J; Fee BE; Hiebert SW; Zambetti GP; Cleveland JL
Oncogene; 2001 Oct; 20(48):6983-93. PubMed ID: 11704823
[TBL] [Abstract][Full Text] [Related]
17. Constitutive expression of FosB and its short form, FosB/SF, induces malignant cell transformation in rat-1A cells.
Kovary K; Rizzo CA; Ryseck RP; Noguchi T; Raynoschek C; Pelosin JM; Bravo R
New Biol; 1991 Sep; 3(9):870-9. PubMed ID: 1931831
[TBL] [Abstract][Full Text] [Related]
18. Dual functions of E2F-1 in a transgenic mouse model of liver carcinogenesis.
Conner EA; Lemmer ER; Omori M; Wirth PJ; Factor VM; Thorgeirsson SS
Oncogene; 2000 Oct; 19(44):5054-62. PubMed ID: 11042693
[TBL] [Abstract][Full Text] [Related]
19. Ectopic expression of PTTG1/securin promotes tumorigenesis in human embryonic kidney cells.
Hamid T; Malik MT; Kakar SS
Mol Cancer; 2005 Jan; 4(1):3. PubMed ID: 15649325
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of proteins HMGA1 induces cell cycle deregulation and apoptosis in normal rat thyroid cells.
Fedele M; Pierantoni GM; Berlingieri MT; Battista S; Baldassarre G; Munshi N; Dentice M; Thanos D; Santoro M; Viglietto G; Fusco A
Cancer Res; 2001 Jun; 61(11):4583-90. PubMed ID: 11389094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
